• Morningstar, ticker NasdaqGS:MORN, has launched the Morningstar PitchBook GenAI 20 Index, focused on pure-play generative AI companies.
• The index tracks leading generative AI firms across their private-to-public life cycle, including companies not typically found in major benchmarks.
• The launch gives investors a new tool to follow and compare activity in the generative AI sector.

Morningstar is introducing this index at a time when its own shares trade at $214.0, with a 1-year return of a 34.1% decline and a 3-year return of a 7.9% decline. Over 5 years, the stock shows a 4.7% decline, while the year-to-date return stands at 1.7%. This mix of near-term stability and longer-term declines provides context for a company that is investing in new index offerings tied to emerging technology themes.

For you as an investor, the PitchBook GenAI 20 Index may serve as a reference point when you compare funds, ETFs, or portfolios that claim exposure to generative AI. While it does not represent a direct investment on its own, it can help you track how this part of the market is evolving and how public and private leaders in generative AI are being grouped for analysis.

Stay updated on the most important news stories for Morningstar by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Morningstar.

The GenAI 20 Index broadens Morningstar's toolkit for institutions and product issuers that want more focused exposure to generative AI, across both private and public markets. For you, this potentially means clearer reference points for any funds or structured products that lean on private AI leaders, at a time when many of those companies are not yet in mainstream benchmarks.

Morningstar Narrative, where this launch may fit in your thesis

There are no established narratives on Morningstar here, but this index launch sits alongside its broader push in research, managed accounts analysis, and index provision. Taken together, these initiatives point to a company leaning into data, analytics, and benchmarks as core strengths. If you are already following Morningstar for its role in indexing and retirement research, the GenAI 20 Index adds another product that connects those capabilities with a high-profile technology theme.

Risks and rewards to keep in mind

• 🎁 The GenAI 20 Index could support new licensing or index-linked products that build on Morningstar's existing index relationships, such as the PIMFA agreement in the UK.
• 🎁 Using PitchBook's private markets data may deepen client reliance on Morningstar's datasets across both private and public equity workflows.
• ⚠️ Generative AI is an early stage theme, so investor interest in pure-play exposure may be uneven across cycles and may affect demand for related index products.
• ⚠️ Indexes tied to fast evolving technologies can face turnover, classification debates, and methodology scrutiny from professional users.

What to watch next

From here, it is worth watching whether asset managers license the GenAI 20 Index for ETFs or structured products and how Morningstar positions it alongside more traditional benchmarks and its retirement research. If you want to see how different investors are framing stories around companies linked to AI themes, check out our Community Narratives hub for a range of perspectives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.